Screening for prostate cancer remains controversial.
Stark
Jennifer R
JR
Department of Epidemiology, Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA. stark@hsph.harvard.edu
Mucci
Lorelei
L
Rothman
Kenneth J
KJ
Adami
Hans-Olov
HO
D003365:Costs and Cost Analysis; D055088:Early Detection of Cancer; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000592:standards; D008875:Middle Aged; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy; D019057:Quality-Adjusted Life Years; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D012680:Sensitivity and Specificity; D016896:Treatment Outcome
D017430:Prostate-Specific Antigen